IP Library Granted Patent US 12703718
Granted Patent B2
US 12703718 · App. 18/547,053 · Granted Aug 11, 2026

Compositions and compounds for co-delivery of uridine and ketoleucine

Inventors: Reid Warren Von Borstel (Potomac, MD); David Michael Simpson (North Bethesda, MD); Rolando Alejandro Garcia Garcia (Germantown, MD)
Assignee: PHARMA CINQ, LLC
C07H19/067A61K31/7072
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12703718
App. No.
18/547,053
Granted
Aug 11, 2026
Kind
B2
Abstract

Compounds and compositions that deliver both uridine and ketoleucine are useful in treating disorders characterized by diminished muscle strength or diminished muscle lean mass. One such a compound is 5′-O-ketoleucyl-2′,3′-di-O-acetyluridine.

Claims (7)

1 . A compound, 5′-O-ketoleucyl-2′,3′-di-O-acetyluridine.

2 . A method of treating a disorder characterized by diminished muscle strength or diminished muscle lean mass in a mammalian subject, comprising administering to the mammalian subject an amount of the compound of claim 1 effective to treat the disorder.

3 . The method of claim 2 , wherein the disorder is selected from the group consisting of muscle-wasting conditions; dynapenia; muscle disuse atrophy; and the muscle wasting and exercise tolerance associated with chronic kidney disease, chronic obstructive pulmonary disease, and chronic heart failure.

4 . The method of claim 3 wherein the muscle-wasting condition is selected from the group consisting of sarcopenia and cachexia.

5 . The method of claim 2 , wherein the mammalian subject is a human subject.

6 . The method of claim 3 , wherein the mammalian subject is a human subject.

7 . The method of claim 4 , wherein the mammalian subject is a human subject.